As global attention on metabolic diseases continues to rise, GLP-1 receptor agonists (GLP-1 RAs) have emerged as a revolutionary breakthrough in the treatment of diabetes and obesity, rapidly transforming the landscape of global healthcare. Multinational giants such as Novo Nordisk and Eli Lilly are dominating the global market with blockbuster products like semaglutide and tirzepatide, making GLP-1-related drugs one of the most heavily invested areas in pharmaceutical R&D.

In this global race driven by "technology + health," China's pharmaceutical force is becoming increasingly significant. With unprecedented speed and focus, we are fully committed to the R&D and industrialization of GLP-1 class drugs.

China accounts for 26% of the global diabetic population and is the second-largest spender on diabetes-related healthcare. The diabetes drug market in China is expected to grow significantly by 2030. Meanwhile, China has the highest number of obese people in the world, and the World Obesity Atlas estimates that the number of obese people in China will increase by 22% to 300 million by 2030.

The trend chart of overweight/obesity prevalence in our country (including predictions) Source: YIMAI TONG
Note: Overweight: BMI 24.0-28.0kg/m^2;
Obesity: BMI ≥ 28.0kg/m^2

Using nationally representative data collected since the 1990s, including the 2015 China National Nutrition and Health Survey Report, the prevalence of hypertension and type 2 diabetes and the number of people with these diseases were predicted by 2030.

Through linear regression analysis, by 2030, the prevalence of hypertension and diabetes in our country may reach 35.4% and 18.5% respectively, with the number of people affected possibly reaching 416 million and 218 million respectively.

The trend chart of hypertension and type 2 diabetes prevalence in our country (including predictions) Source: YIMAI TONG
  China's GLP-1 market will grow rapidly at an annual rate of 23%. With the recommendation of celebrities such as Elon Musk, the popularity of these drugs has further increased.

By 2033, the market size will reach 81 billion RMB (approximately 11.4 billion USD). By then, it is expected that Chinese local companies will capture 20% of the drug market through competitive pricing, extensive sales networks, and better efficacy to meet the needs of an increasingly health-conscious local population.
GLP-1 drug market dynamics
   The global GLP-1 drug market is expanding rapidly, with a compound annual growth rate exceeding 20%, and is expected to surpass $150 billion by 2030.
This is not only a scientific revolution, but also an industrial leap forward. With professional dedication, cutting-edge technology, and a global perspective, we are committed to providing high-quality GLP-1 drug solutions to partners around the world.We are not limited to the Chinese market — we aim to become a key contributor to the global GLP-1 ecosystem.